Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 4/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.34 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754346 | 0.83 | IDH2 (0.40) | IDH2KITNR3C2RPS6KB1AKT1 | |
| SCHEMBL17778564 | 0.83 | IDH2 (0.40) | IDH2KITNR3C2RPS6KB1AKT1 | |
| SCHEMBL19670351 | 0.79 | MAP4K4 (0.43) | TRPV3MAP4K4 | |
| SCHEMBL19670500 | 0.79 | MAP4K4 (0.43) | TRPV3MAP4K4 | |
| SCHEMBL17618458 | 0.78 | TRPV1 (0.41) | IDH2KITNR3C2RPS6KB1AKT1 | |
| SCHEMBL19670542 | 0.78 | RHOA (0.39) | IDH2 | |
| SCHEMBL19706103 | 0.78 | PRKCQ (0.32) | IDH2MAP4K4 | |
| SCHEMBL20733227 | 0.77 | IDH2 (0.40) | IDH2KITNR3C2RPS6KB1AKT1 | |
| SCHEMBL19670315 | 0.77 | HRH3 (0.38) | TRPV3 | |
| SCHEMBL20733153 | 0.77 | GRM5 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IDH2 34/4885KIT 1450/4885NR3C2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.